Elinogrel, a Reversible Platelet Inhibitor, Shows Promising Antiplatelet Activity in Nonurgent PCI

Summary

The Novel Antiplatelet Therapy in Patients Undergoing Nonurgent Percutaneous Coronary Interventions [INNOVATE PCI] trial compared with clopidogrel and elinogrel for platelet inhibition without increasing bleeding risk in patients who were undergoing elective percutaneous coronary intervention.

  • Coronary Artery Disease
  • Interventional Techniques & Devices
  • Cardiology Clinical Trials
  • Thrombotic Disorders
View Full Text
Back to top

Tools

View Full Page PDF
Citation Tools
Email
Elinogrel, a Reversible Platelet Inhibitor, Shows Promising Antiplatelet Activity in Nonurgent PCI
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

Coronary Artery Disease
Interventional Techniques & Devices
Cardiology Clinical Trials
Thrombotic Disorders